Navigation Links
Boston Scientific Launches Third-Generation Platinum Chromium Drug-Eluting Stent
Date:5/19/2009

clude, among other things, statements regarding clinical trials, regulatory approvals, competitive offerings and product performance. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and, future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A - Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A - Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file thereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to al
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Boston Scientific Data Show Real-World Survival Rates for Implantable Cardiac Device Patients Exceed Rates From Clinical Trials
2. Journal of American College of Cardiology Article Reports Fewer Repeat Procedures With Boston Scientifics TAXUS(R) Liberte(R) Stent
3. Boston Scientific Welcomes Publication of HORIZONS AMI Trial Results in New England Journal of Medicine
4. Clinical Data Reinforce Safety and Efficacy of Boston Scientifics Two Drug- Eluting Stent Platforms
5. New England Journal of Medicine Publishes Results from Boston Scientifics Landmark SYNTAX(TM) Trial
6. Boston Scientific Submits Final Modules to FDA for Approval of Second-Generation Small Vessel and Long Lesion Stents
7. Boston Scientific Begins Clinical Trial Enrollment for New Everolimus-Eluting Stent
8. Taxus Atlas Studies Reinforce Safety and Efficacy of Boston Scientifics Next-Generation Taxus Liberte Stent
9. Boston Scientific to Release Broad Range of Clinical Trial Data on the Performance of TAXUS(R) Coronary Stent Systems at TCT 2008
10. Boston Scientific Completes Clinical Trial Enrollment for Third-Generation Drug-Eluting Stent
11. Wound Management Technologies, Inc. Announces Conference Plans in Boston and Additional Clinical Research on CellerateRx(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)...  Novastem, a leader in regenerative medicine, announces ... study for ischemic stroke at Clinica Santa Clarita. ... account for 87 percent of all stroke cases. ... study, entitled "Internal Research Protocol in Combination Therapy ... and Intrathecal Administration of Neural Stem Cells in ...
(Date:12/24/2014)... CHENGDU, China, Dec. 24, 2014 /PRNewswire/  -- Tianyin ... a pharmaceutical company that specializes in the patented ... and active pharmaceutical ingredients (API) released unaudited preliminary ... year 2015. Fiscal Year 2015 Ended ... was $9.7 million compared with $14.7 million in ...
(Date:12/24/2014)... 24, 2014  The International Trade Commission (ITC) issued its ... BMC Medical. In a notice issued on December 23, the ... patent on its humidifier was invalid. BMC President, ... "We are very excited with the ITC,s decision in this ... have taken since the very beginning on the key patents ...
Breaking Medicine Technology:Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 2Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 3Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 4TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 2TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 3TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 4TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 5TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 6TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 7TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 8TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 9TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 10TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 11TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 12ITC Final Decision Goes Against ResMed (RMD) Monumental Win for 3B/BMC 2
(Date:12/25/2014)... HealthDay Reporter WEDNESDAY, Dec. ... chronic illnesses can receive effective, less expensive care from a ... to a team of dedicated health care professionals, a new ... ill and need either hospitalization or a trip to the ... home clinic at the University of Texas in Houston versus ...
(Date:12/25/2014)... Dennis Thompson HealthDay Reporter ... closing in on a "fountain of youth" drug that can ... older adults, a new study suggests. Seniors received a ... that targets a genetic signaling pathway linked to aging and ... The experimental medication, a version of the drug ...
(Date:12/25/2014)... (PRWEB) December 25, 2014 Plugin creators ... ProFire 5k. A fully customizable business presentation tool made ... “Adding the ProFire 5k business tool, users can now ... Austin, CEO of Pixel Film Studios. “ProFire 5k gives ... style to add professionalism to a presentation” , Pixel ...
(Date:12/24/2014)... AlignLife of Wauwatosa loves helping those in the ... holiday season, AlignLife looks forward to their annual toy drive. ... Mahalko-Leonhardt, owner of AlignLife. "It brings our patients as well ... able to give kids toys for Christmas who would be ... of our patients." , The 70 toys were donated to ...
(Date:12/24/2014)... Recently, iFitDress.com, a famous dress manufacturer and retailer, ... $150 . All these items are brand new; they are ... been updated with the new range of high quality prom ... All iFitDress.com’s designs are made according to the latest trends. ... Every outfit from the company is handpicked by skilled tailors. ...
Breaking Medicine News(10 mins):Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 3Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 3Health News:Announcing a new ProFire 5k plugin from Pixel Film Studios for Final Cut Pro X Professionals 2Health News:AlignLife of Wauwatosa Brings Joy to Less Fortunate Families 2Health News:Many Prom Dresses under 150 from Well-known Dress Manufacturer iFitDress.com 2
... Association,of Realtors testified at the Senate Finance Committee hearing ... serve the needs of,its self-employed members. Nearly 30 percent ... primary reason - 84 percent of Realtors who do,not ... believe that tax incentives for the self-employed and for ...
... Inc. (APCapital) (Nasdaq: ACAP ) today announced net,income ... for the third,quarter of 2007. For the first nine ... million, or $3.54 per diluted common share. At,September 30, ... on,10,575,799 shares outstanding, an increase of 10.1% from $23.26 ...
... a Phase II Trial to Evaluate an Immunomodulatory Cell ... York, NY October 25, 2007 The ... Osiris Therapeutics, Inc. (NASDAQ:OSIR) to support a Phase II ... to preserve and regenerate insulin-producing cells in patients newly ...
... in Cancer Control, Volunteerism and,Humanitarianism, ATLANTA, ... and dedication have helped reduce the burden ... American Cancer Society for their work,in cancer ... Society, the nation,s largest voluntary health organization, ...
... show Masimo provides unique benefits in pulse oximetry, ... hemodynamic monitoring IRVINE, Calif., Oct. 25 /PRNewswire-FirstCall/ ... and Low Perfusion pulse oximetry,reported that multiple independent ... presented last week at the 2007 American Society ...
... new information that may help to improve the use of ... vessels in tumors, a process called angiogenesis that is critical ... present there are no reliable methods for determining whether they ... a patient will benefit (or not) from treatment. , ...
Cached Medicine News:Health News:Nearly 30 Percent of Realtors(R) Lack Health Insurance 2Health News:American Physicians Capital, Inc. Reports Third Quarter 2007 Results 2Health News:American Physicians Capital, Inc. Reports Third Quarter 2007 Results 3Health News:American Physicians Capital, Inc. Reports Third Quarter 2007 Results 4Health News:American Physicians Capital, Inc. Reports Third Quarter 2007 Results 5Health News:American Physicians Capital, Inc. Reports Third Quarter 2007 Results 6Health News:American Physicians Capital, Inc. Reports Third Quarter 2007 Results 7Health News:American Physicians Capital, Inc. Reports Third Quarter 2007 Results 8Health News:American Physicians Capital, Inc. Reports Third Quarter 2007 Results 9Health News:American Physicians Capital, Inc. Reports Third Quarter 2007 Results 10Health News:American Physicians Capital, Inc. Reports Third Quarter 2007 Results 11Health News:American Physicians Capital, Inc. Reports Third Quarter 2007 Results 12Health News:American Physicians Capital, Inc. Reports Third Quarter 2007 Results 13Health News:JDRF Partners with Osiris to evaluate an immunomodulatory cell therapy product for type 1 diabetes 2Health News:American Cancer Society Honors Outstanding Contributions to Fight Against Cancer 2Health News:American Cancer Society Honors Outstanding Contributions to Fight Against Cancer 3Health News:American Cancer Society Honors Outstanding Contributions to Fight Against Cancer 4Health News:Breaking Studies - Masimo's Technologies the Focus of Multiple Clinical Studies at Last Week's American Society of Anesthesiologists' Annual Meeting 2Health News:Breaking Studies - Masimo's Technologies the Focus of Multiple Clinical Studies at Last Week's American Society of Anesthesiologists' Annual Meeting 3Health News:Breaking Studies - Masimo's Technologies the Focus of Multiple Clinical Studies at Last Week's American Society of Anesthesiologists' Annual Meeting 4Health News:Breaking Studies - Masimo's Technologies the Focus of Multiple Clinical Studies at Last Week's American Society of Anesthesiologists' Annual Meeting 5Health News:Breaking Studies - Masimo's Technologies the Focus of Multiple Clinical Studies at Last Week's American Society of Anesthesiologists' Annual Meeting 6Health News:Study shows blood markers can help choose best dose for antiangiogenic drugs 2Health News:Study shows blood markers can help choose best dose for antiangiogenic drugs 3
... unique Electro-4 design allows "Four gels in one ... possible to run 200 samples or more in ... four horizontal gels. To ensure even migration, the ... of gels being run. Ideal for high throughput ...
... may be formed directly on the UV-transparent gel ... agarose as it cools, or outside the unit ... Gel is 7.5cm wide 10cm long. Different colors ... (e.g., RNA only). Combs and tape are not ...
... gel is made of high quality PMMA. It features ... protection device.Combs, gel tray and cables are all included ... 6.5x6 (cm), 200 ... 2 (9-well) • 2 ...
... the HE 33 Mini Submarine Unit for nucleic acid ... is designed for very fast separations of DNA restriction ... as a heat-sink. Fill the base with coolant and ... either keeping the unit in a freezer or by ...
Medicine Products: